<code id='D10532F278'></code><style id='D10532F278'></style>
    • <acronym id='D10532F278'></acronym>
      <center id='D10532F278'><center id='D10532F278'><tfoot id='D10532F278'></tfoot></center><abbr id='D10532F278'><dir id='D10532F278'><tfoot id='D10532F278'></tfoot><noframes id='D10532F278'>

    • <optgroup id='D10532F278'><strike id='D10532F278'><sup id='D10532F278'></sup></strike><code id='D10532F278'></code></optgroup>
        1. <b id='D10532F278'><label id='D10532F278'><select id='D10532F278'><dt id='D10532F278'><span id='D10532F278'></span></dt></select></label></b><u id='D10532F278'></u>
          <i id='D10532F278'><strike id='D10532F278'><tt id='D10532F278'><pre id='D10532F278'></pre></tt></strike></i>

          leisure time

          leisure time

          author:focus    Page View:854
          Nick Leschly - Bluebird Bio
          Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

          Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

          The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

          advertisement

          The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          US recommends Americans reconsider traveling to China due to arbitrary law enforcement, exit bans
          US recommends Americans reconsider traveling to China due to arbitrary law enforcement, exit bans

          BEIJING--TheU.S.recommendedAmericansreconsidertravelingtoChinabecauseofarbitrarylawenforcementandexi

          read more
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban

          WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

          read more

          US recommends Americans reconsider traveling to China due to arbitrary law enforcement, exit bans

          BEIJING--TheU.S.recommendedAmericansreconsidertravelingtoChinabecauseofarbitrarylawenforcementandexi